Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
ETFs with VRTX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|5.02%||Merrill Lynch Biotech HOLDRS (BBH)||+22.44 (28.59%)|
|4.23%||iShares NASDAQ Biotechnology Index Fund (IBB)||+59.67 (29.62%)|
|2.12%||Guggenheim S&P 500 Equal Weight Healthcare ETF (RYH)||+17.88 (17.56%)|
|1.87%||Guggenheim S&P 500 Pure Growth ETF (RPG)||+12.62 (19.91%)|
|1.85%||First Trust NASDAQ-100 Ex-Technology Sector Index Fund (QQXT)||+4.57 (14.25%)|
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are in the business of discovering, developing, manufacturing and commercializing small molecule drugs. We invest in scientific innovation to create transformative medicines for patients with serious diseases in specialty markets. Since mid-2011, we have obtained approval for, and initiated commercial sales of, our first two products: KALYDECO (ivacaftor) and INCIVEK (telaprevir). We market KALYDECO in the United States and international markets for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. ... More ...
|Annual EPS Est:||$-1.47|
|Quarterly EPS Est:||-0.79|